Browse studies

Find your next paid study

6 recruiting studies matching your filters

Pilot Study of a Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients c…

NSCLC Stage IVALK Fusion Protein Expression

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05950139

Phase 3

Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or…

NSCLC Stage IV

Estimated

~$10 – $8,750

ImmunityBio, Inc.NCT06745908

Phase 1

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recu…

NSCLC Stage IVNSCLC, Recurrent

Estimated

~$10 – $6,250

University of Kansas Medical CenterNCT04467723

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN)

To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving…

Lung CancerNSCLCNSCLC Stage IV

Estimated

~$10 – $1,125

Jun Zhang, MD, PhDNCT05332925

Phase 2

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therap…

Non Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-small Cell Carcinoma+2 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05657873

Phase 2

A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzu…

Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung Cancer+1 more

Estimated

~$10 – $7,500

Jun Zhang, MD, PhDNCT05859217